Adherence to Weight‐Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Systemic Lupus Erythematosus and Rheumatoid Arthritis: Results of a Quality Improvement Initiative

OBJECTIVE: Hydroxychloroquine (HCQ) is commonly prescribed for the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other rheumatic diseases. To limit retinal toxicity, the 2016 American Academy of Ophthalmology (AAO) guidelines recommended limiting the HCQ dose to 5 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Skorupa, Tara, Shmerling, Robert H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516102/
https://www.ncbi.nlm.nih.gov/pubmed/34363746
http://dx.doi.org/10.1002/acr2.11320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516102/
https://www.ncbi.nlm.nih.gov/pubmed/34363746
http://dx.doi.org/10.1002/acr2.11320

Ejemplares similares